Emergent BioSolutions
Presence
Emergent BioSolutions is one of the...
Emergent BioSolutions is a company listed under the stock ticker EBS (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Emergent BioSolutions
Popular executive movements at Emergent BioSolutions
- Joseph Papa has joined the company as Chief Executive Officer (posted on February 22 2024).
- Haywood Miller, Interim Chief Executive Officer, has left the company (posted on February 22 2024).
- Neal Fowler has joined the company as Director (posted on October 3 2023).
Click here to view some more movements at Emergent BioSolutions
Create your alert
to follow the executive moves at Emergent BioSolutions.
Pharmaceuticals
Emergent BioSolutions has 1,868 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Emergent BioSolutions
- Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency | Emergent BioSolutions Inc.
- Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position | Emergent BioSolutions Inc.
- Emergent BioSolutions Reports Financial Results for Second Quarter 2023 | Emergent BioSolutions Inc.
- Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola | Emergent BioSolutions Inc.
- Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use | Emergent BioSolutions Inc.
- Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023 | Emergent BioSolutions Inc.
- Emergent BioSolutions Announces CEO Transition | Emergent BioSolutions Inc.
- Emergent BioSolutions Reports Financial Results For First Quarter 2023 | Emergent BioSolutions Inc.
- News | Emergent BioSolutions Inc.
- Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic | Emergent BioSolutions Inc.
- View more press releases Close
Social media about Emergent BioSolutions
- Emergent BioSolutions on Wikipedia, Google News & Yahoo Finance
- Emergent BioSolutions on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Zsolt Harsanyi 
Call Emergent BioSolutions at +1 301...
